{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroenteropancreatic+Neuroendocrine+Neoplasm&page=2", "query": { "condition": "Gastroenteropancreatic Neuroendocrine Neoplasm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroenteropancreatic+Neuroendocrine+Neoplasm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:06:24.954Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04711135", "title": "Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumors", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "Lutetium [177Lu] oxodotreotide/dotatate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 11, "start_date": "2022-08-31", "completion_date": "2034-02-06", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 3, "location_summary": "Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711135" }, { "nct_id": "NCT03950609", "title": "Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Carcinoid Tumor", "Digestive System Neuroendocrine Neoplasm", "Multiple Endocrine Neoplasia Type 1", "Neuroendocrine Neoplasm", "Unresectable Carcinoid Tumor" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-07-30", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950609" }, { "nct_id": "NCT03042780", "title": "FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor", "Pancreatic Cancer", "Neuroendocrine Carcinomas of Pancreas", "Islet Cell Carcinoma" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-02-01", "completion_date": "2018-09-07", "has_results": true, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042780" }, { "nct_id": "NCT02420691", "title": "Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Digestive System Neuroendocrine Neoplasm", "Duodenal Neuroendocrine Tumor G1", "Functional Pancreatic Neuroendocrine Tumor", "Gastric Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Nonfunctional Pancreatic Neuroendocrine Tumor", "Thymus Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-08-25", "completion_date": "2019-06-05", "has_results": true, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420691" }, { "nct_id": "NCT04919226", "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT", "type": "DRUG" }, { "name": "CAPTEM (Capecitabine and Temozolomide)", "type": "DRUG" }, { "name": "Amino-Acid Solution", "type": "OTHER" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2021-12-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 14, "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919226" }, { "nct_id": "NCT05773274", "title": "Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Digestive System Neuroendocrine Tumor G2", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Digestive System Neuroendocrine Tumor G2" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-01-12", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05773274" }, { "nct_id": "NCT02955069", "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Well-differentiated Non-functional NET of Thoracic Origin", "Well-differentiated Non-functional NET of Gastrointestinal Origin", "Well-differentiated Non-functional NET of Pancreatic Origin", "Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2017-02-14", "completion_date": "2020-05-13", "has_results": true, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 7, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955069" }, { "nct_id": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GEP-NET", "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Tumor Disease", "Neuroendocrine Tumors", "Carcinoid", "Carcinoid Tumor", "Pancreatic NET" ], "interventions": [ { "name": "RYZ101", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Lanreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RayzeBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2022-03-24", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477576" }, { "nct_id": "NCT04234568", "title": "Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Triapine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-07-20", "completion_date": "2027-03-13", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234568" }, { "nct_id": "NCT07006727", "title": "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Carcinoma", "Large Cell Neuroendocrine Carcinoma of the Lung", "Neuroendocrine Prostate Cancer", "Gastroenteropancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "225Ac-ETN029", "type": "DRUG" }, { "name": "111In-ETN029", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 116, "start_date": "2025-10-16", "completion_date": "2031-08-29", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T09:06:24.954Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07006727" } ] }